10-Q: Sonoma Pharma Reports Strong Revenue Growth Amidst Liquidity Concerns

Sonoma Pharmaceuticals, Inc. reported significant revenue growth in its latest quarter, but faces substantial doubt about its ability to continue as a going concern due to ongoing losses and cash burn.

Summary

• Total revenues for the six months ended September 30, 2025, increased by 38% to $9.619 million, up from $6.970 million in the prior year period.
• Gross profit for the six months ended September 30, 2025, rose by 34% to $3.584 million, compared to $2.667 million in the same period last year.
• Net loss for the six months ended September 30, 2025, was $(1.775) million, a slight increase from $(1.753) million in the prior year.
• Net cash used in operating activities significantly increased to $(2.650) million for the six months ended September 30, 2025, compared to $(558) thousand in the prior year.
• Cash and cash equivalents decreased to $3.035 million as of September 30, 2025, from $5.374 million at March 31, 2025.
• The company's accumulated deficit grew to $199.581 million as of September 30, 2025.
• Management has expressed substantial doubt about the company's ability to continue as a going concern within one year.

Sentiment

Score: 3

Explanation: While revenue growth is strong across several key regions, the significant increase in net cash used in operating activities, the substantial decline in cash and cash equivalents, and the explicit 'going concern' warning indicate severe liquidity challenges and financial instability. The slight increase in net loss further contributes to a negative outlook, despite improved operating loss and SG&A efficiency relative to revenue.

Positives

• Total revenues increased by 38% to $9.619 million for the six months ended September 30, 2025, demonstrating strong top-line growth.
• United States revenue surged by 86% to $2.454 million for the six months, driven by human health care and over-the-counter animal health care products.
• European revenue increased by 30% to $3.619 million for the six months, reflecting a general increase in demand.
• Rest of the World revenue saw a substantial increase of 180% to $731 thousand for the six months, primarily due to timing of customer orders.
• Loss from operations improved to $(1.432) million for the six months ended September 30, 2025, from $(2.023) million in the prior year.
• Selling, general and administrative expenses as a percentage of revenues decreased to 40% for the six months ended September 30, 2025, from 53% in the prior year, indicating improved efficiency relative to revenue.

Negatives

• Net loss slightly worsened to $(1.775) million for the six months ended September 30, 2025, compared to $(1.753) million in the prior year.
• Cash and cash equivalents decreased significantly by $2.339 million to $3.035 million at September 30, 2025, from $5.374 million at March 31, 2025.
• Net cash used in operating activities increased substantially to $(2.650) million for the six months ended September 30, 2025, from $(558) thousand in the prior year, indicating higher cash burn.
• Working capital decreased to $8.179 million at September 30, 2025, from $8.552 million at March 31, 2025.
• Latin America revenue decreased by 19% to $1.096 million for the six months ended September 30, 2025, primarily due to timing of customer orders for overflow manufacturing.
• Gross profit as a percentage of revenues slightly declined to 37% for the six months ended September 30, 2025, from 38% in the prior year.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern within one year due to a history of losses and significant cash usage in operations.
• Dependence on a few key customers for a significant portion of revenues, which may fluctuate unpredictably.
• Exposure to foreign currency devaluation risks, particularly for the Mexico Peso and the Euro versus the US dollar.
• A substantial Mexico tax liability, including intercompany debt and unpaid technical assistance charges, is due in 2027.
• Inability to secure additional capital on commercially acceptable terms could lead to cost reduction measures and delays in product commercialization.
• Risks associated with global economic conditions, potential tariffs, and changes to trade policies.
• Challenges in complying with complex federal and state fraud and abuse laws, including anti-kickback laws.
• Risks related to changes in healthcare laws and regulations.
• Difficulty in attracting and retaining qualified directors, officers, and employees.
• Risks associated with expanding and commercializing products in new markets outside wound care.
• Potential for intellectual property infringement and the ability to protect existing intellectual property.
• Need to indemnify distributors or other third parties.
• Risks inherent in conducting a significant portion of business outside the United States.
• Vulnerability to information technology and infrastructure breaches.

Future Outlook

Management believes it has access to additional capital through public or private equity offerings, debt financings, or corporate collaborations, but cannot assure availability on commercially acceptable terms. If unable to secure additional capital, the company may need to reduce costs, potentially delaying product commercialization efforts critical to its business plan. The company continues to evaluate the impact of the One Big Beautiful Bill Act (OBBBA) tax reform legislation on its financial statements, anticipating an insignificant impact to deferred tax assets and liabilities and income taxes payable in the period of enactment.

Management Comments

• Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed.
• If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company's continued efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of the Company.
• This uncertainty along with the Company's history of losses indicates that there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.
• At this time, management believes there are sufficient assets on the balance sheet to cover any tax obligation without interrupting our operations or business (referring to the Mexico tax liability due in 2027).

Industry Context

Sonoma Pharmaceuticals operates in the global healthcare market, specializing in stabilized hypochlorous acid (HOCl) products for wound care, eye care, dermatology, podiatry, animal health, and disinfectants. The company's focus on clinically proven HOCl technology positions it in a niche but growing segment of the healthcare industry, emphasizing safety and efficacy. The reported revenue growth, particularly in the US and Europe, suggests increasing market acceptance for its diverse product portfolio. However, the significant cash burn and going concern warning highlight the capital-intensive nature of the pharmaceutical and healthcare product development and commercialization industry, where sustained profitability can be challenging for smaller players.

Management Changes

Legal Proceedings

• The company may be involved in legal matters arising in the ordinary course of business, including proprietary technology. Management believes such matters are currently insignificant, but they could have a material adverse effect.

Stakeholder Impact

• Shareholders face significant risk due to the 'going concern' warning and potential need for further capital raises, which could dilute existing equity.
• Employees, particularly key executives, are subject to employment agreement changes and potential terminations, as evidenced by the recent COO departure.
• Customers may experience delays in product commercialization if the company is unable to secure additional capital and is forced to reduce costs.
• Creditors face increased risk due to the company's history of losses and declining cash position, particularly concerning the Mexico tax liability due in 2027.

Next Steps

• Continue efforts to commercialize products, which is critical to the realization of the business plan.
• Evaluate options to limit exposure to the substantial Mexico tax liability due in 2027.
• Monitor global economic conditions, tariffs, and trade policies.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) tax reform legislation on consolidated financial statements.
• Adopt Accounting Standards Update (ASU) 2023-09 in the Annual Report on Form 10-K for the year ended March 31, 2026.

Key Dates

Recommendation

Despite strong revenue growth in several segments, the company's severe liquidity issues, evidenced by a significant decline in cash and a substantial increase in cash used in operations, coupled with an explicit 'going concern' warning, present an extremely high-risk profile. The accumulated deficit continues to grow, and while management indicates access to capital, there's no assurance of favorable terms. The termination of a key executive and the looming Mexico tax liability further add to the uncertainty. A seasoned investor would view these factors as critical red flags, suggesting a 'sell' recommendation due to the high probability of further share price depreciation and potential for significant capital loss.

Keywords

Sonoma Pharmaceuticals, SNOA, 10-Q, Quarterly Report, Hypochlorous Acid, HOCl, Wound Care, Dermatology, Animal Health, Financial Results, Revenue Growth, Net Loss, Cash Flow, Going Concern, Biotechnology, Healthcare, SEC Filing